1. Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus–related cirrhosis 
Derek Patel, Norah A. Terrault, Francis Y. Yao, Nathan M. Bass, Uri Ladabaum 
Clinical Gastroenterology and Hepatology 
Volume 3, Issue 1, Pages (January 2005)
DOI: /S (04)
Copyright © 2005 American Gastroenterological Association Terms and Conditions

2. Figure 1
Natural History model. Arrows represent possible transitions during each 6-month cycle. Patients enter the model with compensated cirrhosis and might develop decompensated cirrhosis, HCC, both, or might die. Surveillance and treatment strategies were superimposed on this model.
Clinical Gastroenterology and Hepatology 2005 3, 75-84DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

3. Figure 2
Calibration of tumor growth rate. The transition probability between small, medium, and large HCC was adjusted to yield a tumor growth rate that is consistent with published in vivo HCC growth studies. Data from references 33 and 34.
Clinical Gastroenterology and Hepatology 2005 3, 75-84DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

4. Figure 3
Effectiveness and costs of surveillance and treatment strategies. The incremental gains in QALYs afforded by progressively more effective strategies were achieved at incremental costs/QALY (reflected by the slope between points) within a relatively narrow range.
Clinical Gastroenterology and Hepatology 2005 3, 75-84DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions

5. Figure 4
One-way sensitivity analysis for Surveillance/CLT vs Natural History. Effectiveness (A) and cost-effectiveness (B) depended most on CLT outcomes and costs and the epidemiology of cirrhosis and HCC, but not the attributes of the surveillance tests.
Clinical Gastroenterology and Hepatology 2005 3, 75-84DOI: ( /S (04) )
Copyright © 2005 American Gastroenterological Association Terms and Conditions